TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients

被引:63
作者
Halvorsen, Ann R. [1 ]
Silwal-Pandit, Laxmi [1 ]
Meza-Zepeda, Leonardo A. [2 ,3 ]
Vodak, Daniel [2 ]
Phuong Vu [1 ]
Sagerup, Camilla [1 ]
Hovig, Eivind [2 ,4 ,5 ]
Myklebost, Ola [2 ]
Borresen-Dale, Anne-Lise [1 ,6 ]
Brustugun, Odd T. [1 ,7 ]
Helland, Aslaug [1 ,7 ]
机构
[1] Norwegian Radium Hosp, Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway
[2] Oslo Univ Hosp, Inst Canc Res, Dept Tumor Biol, N-0450 Oslo, Norway
[3] Oslo Univ Hosp, Inst Canc Res, Dept Core Facil, Genom Core Facil, N-0450 Oslo, Norway
[4] Univ Oslo, Dept Informat, Oslo, Norway
[5] Oslo Univ Hosp, Inst Canc Genet & Informat, N-0450 Oslo, Norway
[6] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway
[7] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Oncol, Oslo, Norway
来源
FRONTIERS IN GENETICS | 2016年 / 7卷
关键词
P53; MUTATIONS; SOMATIC MUTATIONS; SURVIVAL; GENE;
D O I
10.3389/fgene.2016.00085
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: TP53 mutations are among the most common mutations found in lung cancers, identified as an independent prognostic factor in many types of cancers. The purpose of this study was to investigate the frequency and prognostic impact of TP53 mutations in never-smokers and in different histological subtypes of lung cancer. Methods: We analyzed tumor tissue from 394 non-small cell carcinomas including adenocarcinomas (n = 229), squamous cell carcinomas (n = 112), large cell carcinomas (n = 30), and others (n = 23) for mutations in TP53 by the use of Sanger sequencing (n = 394) and next generation sequencing (n = 100). Results: TP53 mutations were identified in 47.2% of the samples, with the highest frequency (65%) of mutations among squamous cell carcinomas. Among never smokers, 36% carried a TP53 mutation, identified as a significant independent negative prognostic factor in this subgroup. For large cell carcinomas, a significantly prolonged progression free survival was found for those carrying a TP53 mutation. In addition, the frequency of frameshift mutations was doubled in squamous cell carcinomas (20.3%) compared to adenocarcinomas (9.1 %). Conclusion: TP53 mutation patterns differ between the histological subgroups of lung cancers, and are also influenced by smoking history. This indicates that the histological subtypes in lung cancer are genetically different, and that smoking-induced TP53 mutations may have a different biological impact than TP53 mutations occurring in never-smokers.
引用
收藏
页数:10
相关论文
共 31 条
  • [1] Molecular basis of the Li-Fraumeni syndrome:: an update from the French LFS families
    Bougeard, G.
    Sesboue, R.
    Baert-Desurmont, S.
    Vasseur, S.
    Martin, C.
    Tinat, J.
    Brugieres, L.
    Chompret, A.
    Paillerets, B. Bressac-de
    Stoppa-Lyonnet, D.
    Bonaiti-Pellie, C.
    Frebourg, T.
    [J]. JOURNAL OF MEDICAL GENETICS, 2008, 45 (08) : 535 - 538
  • [2] Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
    Cibulskis, Kristian
    Lawrence, Michael S.
    Carter, Scott L.
    Sivachenko, Andrey
    Jaffe, David
    Sougnez, Carrie
    Gabriel, Stacey
    Meyerson, Matthew
    Lander, Eric S.
    Getz, Gad
    [J]. NATURE BIOTECHNOLOGY, 2013, 31 (03) : 213 - 219
  • [3] Comprehensive molecular profiling of lung adenocarcinoma
    Collisson, Eric A.
    Campbell, Joshua D.
    Brooks, Angela N.
    Berger, Alice H.
    Lee, William
    Chmielecki, Juliann
    Beer, David G.
    Cope, Leslie
    Creighton, Chad J.
    Danilova, Ludmila
    Ding, Li
    Getz, Gad
    Hammerman, Peter S.
    Hayes, D. Neil
    Hernandez, Bryan
    Herman, James G.
    Heymach, John V.
    Jurisica, Igor
    Kucherlapati, Raju
    Kwiatkowski, David
    Ladanyi, Marc
    Robertson, Gordon
    Schultz, Nikolaus
    Shen, Ronglai
    Sinha, Rileen
    Sougnez, Carrie
    Tsao, Ming-Sound
    Travis, William D.
    Weinstein, John N.
    Wigle, Dennis A.
    Wilkerson, Matthew D.
    Chu, Andy
    Cherniack, Andrew D.
    Hadjipanayis, Angela
    Rosenberg, Mara
    Weisenberger, Daniel J.
    Laird, Peter W.
    Radenbaugh, Amie
    Ma, Singer
    Stuart, Joshua M.
    Byers, Lauren Averett
    Baylin, Stephen B.
    Govindan, Ramaswamy
    Meyerson, Matthew
    Rosenberg, Mara
    Gabriel, Stacey B.
    Cibulskis, Kristian
    Sougnez, Carrie
    Kim, Jaegil
    Stewart, Chip
    [J]. NATURE, 2014, 511 (7511) : 543 - 550
  • [4] Core Team R, 2013, R LANGUAGE ENV STAT
  • [5] Somatic mutations affect key pathways in lung adenocarcinoma
    Ding, Li
    Getz, Gad
    Wheeler, David A.
    Mardis, Elaine R.
    McLellan, Michael D.
    Cibulskis, Kristian
    Sougnez, Carrie
    Greulich, Heidi
    Muzny, Donna M.
    Morgan, Margaret B.
    Fulton, Lucinda
    Fulton, Robert S.
    Zhang, Qunyuan
    Wendl, Michael C.
    Lawrence, Michael S.
    Larson, David E.
    Chen, Ken
    Dooling, David J.
    Sabo, Aniko
    Hawes, Alicia C.
    Shen, Hua
    Jhangiani, Shalini N.
    Lewis, Lora R.
    Hall, Otis
    Zhu, Yiming
    Mathew, Tittu
    Ren, Yanru
    Yao, Jiqiang
    Scherer, Steven E.
    Clerc, Kerstin
    Metcalf, Ginger A.
    Ng, Brian
    Milosavljevic, Aleksandar
    Gonzalez-Garay, Manuel L.
    Osborne, John R.
    Meyer, Rick
    Shi, Xiaoqi
    Tang, Yuzhu
    Koboldt, Daniel C.
    Lin, Ling
    Abbott, Rachel
    Miner, Tracie L.
    Pohl, Craig
    Fewell, Ginger
    Haipek, Carrie
    Schmidt, Heather
    Dunford-Shore, Brian H.
    Kraja, Aldi
    Crosby, Seth D.
    Sawyer, Christopher S.
    [J]. NATURE, 2008, 455 (7216) : 1069 - 1075
  • [6] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Dikshit, Rajesh
    Eser, Sultan
    Mathers, Colin
    Rebelo, Marise
    Parkin, Donald Maxwell
    Forman, David
    Bray, Freddie
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) : E359 - E386
  • [7] Smoking, p53 Mutation, and Lung Cancer
    Gibbons, Don L.
    Byers, Lauren A.
    Kurie, Jonathan M.
    [J]. MOLECULAR CANCER RESEARCH, 2014, 12 (01) : 3 - 13
  • [8] Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies
    Goldstein, I.
    Marcel, V.
    Olivier, M.
    Oren, M.
    Rotter, V.
    Hainaut, P.
    [J]. CANCER GENE THERAPY, 2011, 18 (01) : 2 - 11
  • [9] Comprehensive genomic characterization of squamous cell lung cancers
    Hammerman, Peter S.
    Lawrence, Michael S.
    Voet, Douglas
    Jing, Rui
    Cibulskis, Kristian
    Sivachenko, Andrey
    Stojanov, Petar
    McKenna, Aaron
    Lander, Eric S.
    Gabriel, Stacey
    Getz, Gad
    Sougnez, Carrie
    Imielinski, Marcin
    Helman, Elena
    Hernandez, Bryan
    Pho, Nam H.
    Meyerson, Matthew
    Chu, Andy
    Chun, Hye-Jung E.
    Mungall, Andrew J.
    Pleasance, Erin
    Robertson, A. Gordon
    Sipahimalani, Payal
    Stoll, Dominik
    Balasundaram, Miruna
    Birol, Inanc
    Butterfield, Yaron S. N.
    Chuah, Eric
    Coope, Robin J. N.
    Corbett, Richard
    Dhalla, Noreen
    Guin, Ranabir
    Hirst, Anhe Carrie
    Hirst, Martin
    Holt, Robert A.
    Lee, Darlene
    Li, Haiyan I.
    Mayo, Michael
    Moore, Richard A.
    Mungall, Karen
    Nip, Ka Ming
    Olshen, Adam
    Schein, Jacqueline E.
    Slobodan, Jared R.
    Tam, Angela
    Thiessen, Nina
    Varhol, Richard
    Zeng, Thomas
    Zhao, Yongjun
    Jones, Steven J. M.
    [J]. NATURE, 2012, 489 (7417) : 519 - 525
  • [10] Hallmarks of Cancer: The Next Generation
    Hanahan, Douglas
    Weinberg, Robert A.
    [J]. CELL, 2011, 144 (05) : 646 - 674